Abstract:
Un anticuerpo o un fragmento de unión a antígeno del mismo que tiene una afinidad de unión específica a un epítope que se encuentra dentro del dominio 3 del receptor 2 del factor de crecimiento endotelial vascular humano (VEGFR2; SEQ ID NO: 74), en donde el epítope dentro del dominio 3 del VEGFR2 se encuentra entre los residuos de aminoácidos 250 y 270 de SEQ ID NO: 74, y además en donde el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena pesada (VH) y una región variable de cadena ligera (VL), la VH comprende VH CDR1, VH CDR2 y VH CDR3 y la VL comprende VL CDR1, VL CDR2 y VL CDR3, en donde: la VH CDR1, VH CDR2 y VH CDR3 comprenden la secuencia de aminoácidos de SEQ ID NO: 6, SEQ ID NO: 7 y SEQ ID NO: 8, respectivamente; y la VL CDR1, VL CDR2 y VL CDR3 comprenden la secuencia de aminoácidos de SEQ ID NO: 9, Asp Ala Ser y SEQ ID NO: 73, respectivamente.
Abstract:
The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Abstract:
An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.
Abstract:
The present disclosure relates to compositions and methods of use comprising antibodies or binding fragments thereof further comprising universal Fc glycoforms.
Abstract:
anticorpo anti-c-met e métodos para utilização do mesmo. os anticorpos que ligam a c-met são fornecidos aqui, bem como composições relacionadasl e métodos do uso. os métodos do uso abrangem a terapia de câncer e a diagnóstica. em certas modalidades, os anticorpos ligam o antígeno de superfície celular mamífero (p.ex., o antígeno de superfície celulars cancerosas). os anticorpos também podem ser endocitados para ligar a células. o que de células pode ser visado pelos anticorpos incluem carcinomas, tais como aqueles em pulmão, rim, fígado, estômago, peito, e cérebro, etc.
Abstract:
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.
Abstract:
This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.